Sudarshan Pharma Board Approves 9.50% Stake Acquisition in MedTherapy Biotechnology
Sudarshan Pharma Industries Ltd 路 Others (Uncategorized) 路 06 Sept 2026, 1:04 am
Sudarshan Pharma Board Approves 9.50% Stake Acquisition in MedTherapy Biotechnology Sudarshan Pharma Industries approved acquiring 24,23,675.64 equity shares (9.50% stake) of US-based MedTherapy Biotechnology Inc. via an all-cash transaction in USD, expected to close by 31st Mar'27. Additionally, promoters Hemal Mehta and Sachin Mehta will acquire 1.50% each (3,82,685.63 shares each). MedTherapy Biotech is a Boston-based CAR-T cell CDMO with manufacturing in New Delhi and R&D in Boston. The acquisition enables Sudarshan Pharma to establish a US footprint, access distribution networks, and broaden into cell and gene therapy offerings.
Original exchange filing (PDF)
More announcements from Sudarshan Pharma Industries Ltd
- Pursuant to Regulation 30 and other applicable Regulations, if any, of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations''), we inform .... 路 09 Nov 2026
- In terms of Regulation 30 read with Para A of Part A of Schedule III to the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby submit the updated Investor .... 路 07 Nov 2026
- In continuation of the Company''s letter dated 30/Oct/2026 (ref. no. SPIL/CS/2026-2027/72), the Board of Directors at its Meeting held on 29/Oct/2026 have approved the proposal to raising .... 路 31 Oct 2026
- This is to inform you that the Board of Directors of the Company at its Board Meeting held on 29/Oct/2026 has approved the proposal to raising funds through issue and allotment of up to .... 路 30 Oct 2026
- We are submitting herewith the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/Sep/2026 路 30 Oct 2026
- We are submitting the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/Sep/2026 路 30 Oct 2026
- Sudarshan Pharma Industries Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Fund raising. 路 29 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 and Fund Raising 路 29 Oct 2026
